Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

نویسندگان

  • T E Starzl
  • K Abu-Elmagd
  • A Tzakis
  • J J Fung
  • K A Porter
  • S Todo
چکیده

FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already are part of our every day transplant practices, as well as those which are presently impractical. Immune intervention for serious autoimmune diseases also should be a more attractive option with this drug. Lessons are still being learned about dosage and what determines safe dose schedules. At a basic level, the study of FK 506 and its comparison to CyA may have shed light on mechanisms and characteristics of the whole class of so-called macrolide immunosuppresants and their cytosolic binding sites.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Liver, kidney, and thoracic organ transplantation under FK 506.

The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85...

متن کامل

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

WITH the use of Cy A for clinical liver transplantation, I-year survival rates have approached 70%. Nevertheless, allograft rejection continues to be the most common cause of retransplantation and death. Clinical rejection occurs in 70% ofliver allograft recipients on CyA and steroid therapy. 1 In addition, nephrotoxicity is the principal and dose-limiting side effect of Cy A. Chronic renal dam...

متن کامل

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

I N initial clinical trials of organ transplanta.tion, F~. 5~ has shown remarkable immunosuppressive activity. The drug is very lipophilic. metabolized in the liver, and predominantly eliminated through the bile. 2 Hepatic dysfunction was expected to alter the pharmacokinetics of FK 506. Hepatic dysfunction is also known to alter the absorption of lipid soluble drugs. 3 This is related to the l...

متن کامل

Preliminary Communication Kidney Transplantation Under FK 506

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13...

متن کامل

Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.

FK 506 is a new macrolide with potent immunosuppressive activity. Use of this drug is associated with reduced incidence of rejection following liver. kidney. and heart transplantation. 1-4 Recently, FK 506 has been shown to be effective in small bowel transplantation. S It is known that FK 506 absorption is not influenced by the presence or absence of bile.6--8 The aims of this study are to: (\...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Transplantation proceedings

دوره 23 1 Pt 2  شماره 

صفحات  -

تاریخ انتشار 1991